Thymoquinone regulates gene expression levels in morphine addiction pathways in opioid receptor expressing cells (U87 MG)

Bibliographic Details
Format: Restricted Document
_version_ 1860797093038260224
building INTELEK Repository
caption Electronic Journal of Biology
collection Online Access
collectionurl https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection407072
date 2017-05-12 19:21:12
format Restricted Document
id 11344
institution UniSZA
originalfilename 5564-01-FH02-FP-18-12200.pdf
person Mohamad N
recordtype oai_dc
resourceurl https://intelek.unisza.edu.my/intelek/pages/view.php?ref=11344
spelling 11344 https://intelek.unisza.edu.my/intelek/pages/view.php?ref=11344 https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection407072 Restricted Document Article Journal application/pdf 8 Adobe Acrobat Pro DC 20 Paper Capture Plug-in 1.7 Electronic Journal of Biology Mohamad N 2017-05-12 19:21:12 xmp.id:05365f34-079d-b041-ab19-b4a5b7e53d7c Thymoquinone U87MG RNA-sequencing Morphine addiction. 5564-01-FH02-FP-18-12200.pdf UniSZA Private Access Thymoquinone regulates gene expression levels in morphine addiction pathways in opioid receptor expressing cells (U87 MG) Electronic Journal of Biology Background: New drugs are continuously being developed for the treatment of opioid dependence individuals. Thymoquinone is one of the drugs that exhibits inhibitory characteristics based on in vivo and in vitro models. Aim: This study further investigates the effects of thymoquinone on human global gene expression from opioid receptor expressing cell line (OREC) using RNA sequencing technology. The cell line that we used was human monoglioma cancer cells (U87 MG). Method: The quantification of RNA samples was carried out using an Agilent 2100 Bioanalyser to determine the RNA integrity number (RIN). Samples with RIN>9.4 were used for further analysis. The universal human reference RNA was used as the common reference. The samples were treated with morphine alone (35 µM), morphine with methadone (162 µM), morphine with methadone and TQ (61 μM) and morphine with TQ for 48 h. The control cells were treated with an equivalent volume of vehicle in growth media. Total RNA was isolated from the U87 MG cells using the RNA mini kit’s protocol (Geneaid) and quantified using a BioDrop 2000c spectrophotometer. After mRNA enrichment and cDNA synthesis, the amplified cDNA fragments were paired-end sequencing using Illumina sequencing system with 2*150 sequencing method and subjected to subsequent bioinformatics analysis. Findings: The results showed that thymoquinone upregulated phosphodiesterase 1 A (PDE1A) genes, gamma-aminobutyric acid type A receptor theta subunit (GABRQ) and G protein subunit beta 3 (GNG3) genes in which these genes were down regulated by the chronic morphine. Conclusion: These findings indicate that thymquinone targets specific genes in morphine addiction pathways. 13 2 167-172
spellingShingle Thymoquinone regulates gene expression levels in morphine addiction pathways in opioid receptor expressing cells (U87 MG)
subject Thymoquinone
U87MG
RNA-sequencing
Morphine addiction.
summary Background: New drugs are continuously being developed for the treatment of opioid dependence individuals. Thymoquinone is one of the drugs that exhibits inhibitory characteristics based on in vivo and in vitro models. Aim: This study further investigates the effects of thymoquinone on human global gene expression from opioid receptor expressing cell line (OREC) using RNA sequencing technology. The cell line that we used was human monoglioma cancer cells (U87 MG). Method: The quantification of RNA samples was carried out using an Agilent 2100 Bioanalyser to determine the RNA integrity number (RIN). Samples with RIN>9.4 were used for further analysis. The universal human reference RNA was used as the common reference. The samples were treated with morphine alone (35 µM), morphine with methadone (162 µM), morphine with methadone and TQ (61 μM) and morphine with TQ for 48 h. The control cells were treated with an equivalent volume of vehicle in growth media. Total RNA was isolated from the U87 MG cells using the RNA mini kit’s protocol (Geneaid) and quantified using a BioDrop 2000c spectrophotometer. After mRNA enrichment and cDNA synthesis, the amplified cDNA fragments were paired-end sequencing using Illumina sequencing system with 2*150 sequencing method and subjected to subsequent bioinformatics analysis. Findings: The results showed that thymoquinone upregulated phosphodiesterase 1 A (PDE1A) genes, gamma-aminobutyric acid type A receptor theta subunit (GABRQ) and G protein subunit beta 3 (GNG3) genes in which these genes were down regulated by the chronic morphine. Conclusion: These findings indicate that thymquinone targets specific genes in morphine addiction pathways.
title Thymoquinone regulates gene expression levels in morphine addiction pathways in opioid receptor expressing cells (U87 MG)
title_full Thymoquinone regulates gene expression levels in morphine addiction pathways in opioid receptor expressing cells (U87 MG)
title_fullStr Thymoquinone regulates gene expression levels in morphine addiction pathways in opioid receptor expressing cells (U87 MG)
title_full_unstemmed Thymoquinone regulates gene expression levels in morphine addiction pathways in opioid receptor expressing cells (U87 MG)
title_short Thymoquinone regulates gene expression levels in morphine addiction pathways in opioid receptor expressing cells (U87 MG)
title_sort thymoquinone regulates gene expression levels in morphine addiction pathways in opioid receptor expressing cells (u87 mg)